Akari Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akari Therapeutics Plc on March 17, 2026. The filing addresses a material modification to the rights of security holders regarding the company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action regarding share structure rather than financial performance results.
Material Changes
- ADS Ratio Change: The company plans to change the ADS ratio from 1 ADS representing 2,000 Ordinary Shares to 1 ADS representing 80,000 Ordinary Shares.
- Reverse Split: This change constitutes a 1-for-40 reverse split of issued and outstanding ADSs.
- Ordinary Shares: The change will have no effect on the underlying Ordinary Shares.
- Effective Date: The Ratio Change is expected to be effective on or about March 31, 2026.
Outlook, Risks, and Management Commentary
Management expects the market price per ADS to increase proportionally to the reverse split. However, the company explicitly states it can give no assurance that the Ratio Change will result in satisfying or maintaining the minimum bid price requirement of The Nasdaq Stock Market LLC.
Investor Verification Checklist
- Confirm the exact effective date of the 1-for-40 ADS reverse split (expected March 31, 2026).
- Verify the company's current compliance status with Nasdaq's minimum bid price requirement.
- Review the attached press release (Exhibit 99.1) for additional details on the rationale for the split.
- Monitor subsequent filings to confirm if the minimum bid price requirement is met post-split.